AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company’s history roots back to the year 1913 when Astra business was formed. 

CEO
Pascal Soriot, MBA, DVM
CEOPascal Soriot, MBA, DVM
Employees
94,300
Employees94,300
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1992
Founded1992
Employees
94,300
Employees94,300

AZN Key Statistics

Market cap
283.79B
Market cap283.79B
Price-Earnings ratio
29.98
Price-Earnings ratio29.98
Dividend yield
1.69%
Dividend yield1.69%
Average volume
5.44M
Average volume5.44M
High today
$91.83
High today$91.83
Low today
$90.51
Low today$90.51
Open price
$90.61
Open price$90.61
Volume
5.72M
Volume5.72M
52 Week high
$91.91
52 Week high$91.91
52 Week low
$61.24
52 Week low$61.24

Stock Snapshot

AstraZeneca(AZN) stock is priced at $91.48, giving the company a market capitalization of 283.79B. It carries a P/E multiple of 29.98 and pays a dividend yield of 1.7%.

On 2025-11-25, AstraZeneca(AZN) stock traded between a low of $90.51 and a high of $91.83. Shares are currently priced at $91.48, which is +1.1% above the low and -0.4% below the high.

AstraZeneca(AZN) shares are trading with a volume of 5.72M, against a daily average of 5.44M.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $91.91 at its peak.

During the past year, AstraZeneca(AZN) stock moved between $61.24 at its lowest and $91.91 at its peak.

AZN News

TipRanks 1h
AstraZeneca: Strong Growth Potential with Robust Pipeline and Attractive Valuation

In a report released today, Sachin Jain from Bank of America Securities reiterated a Buy rating on AstraZeneca, with a price target of p16,500.00. TipRanks Blac...

Benzinga 17h
AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows

Hong Kong-based Harbour BioMed announced on Sunday an update and advancement of its global strategic collaboration with AstraZeneca Plc (NASDAQ:AZN) , initially...

AstraZeneca Doubles Down On US Biologics Buildout As Drug Discovery Partnership Grows
TipRanks 1d
AstraZeneca’s $2 Billion Maryland Expansion to Boost US Medicine Supply Chain

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...

Analyst ratings

81%

of 31 ratings
Buy
80.6%
Hold
16.1%
Sell
3.2%

More AZN News

TipRanks 1d
Harbour BioMed advances collaboration with AstraZeneca

Harbour BioMed announced an update and advancement of its global strategic collaboration with AstraZeneca (AZN), originally established in March 2025. The colla...

TipRanks 1d
HBM Holdings Enhances Collaboration with AstraZeneca for Biotherapeutic Development

TipRanks Black Friday Sale Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence. Subscribe to Tip...

Nasdaq 3d
AstraZeneca To Invest $2 Billion In Maryland Manufacturing Expansion

(RTTNews) - AstraZeneca announced plans to invest $2 billion to expand its long-standing manufacturing presence in Maryland. The investment includes a major exp...

AstraZeneca To Invest $2 Billion In Maryland Manufacturing Expansion
CNBC 3d
AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer - CNBC

...

AstraZeneca CEO Pascal Soriot goes one-on-one with Jim Cramer - CNBC
Nasdaq 3d
Why AstraZeneca Stock Bumped Higher Today

Key Points The pharmaceutical giant is plowing billions of dollars into expanding its drug-making capacity. It has ambitious plans for two facilities in Maryl...

Why AstraZeneca Stock Bumped Higher Today
Seeking Alpha 4d
AstraZeneca expands U.S. production footprint with $2B investment in Maryland

AstraZeneca (AZN) on Friday announced plans to invest $2B in Maryland to boost its U.S. production capacity with a sizable expansion of an existing biologics fa...

AstraZeneca expands U.S. production footprint with $2B investment in Maryland
Benzinga 5d
FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio

On Thursday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Koselugo (selumetinib) for adult patients with neurofibromatosi...

FDA Approval Delivers Momentum For AstraZeneca's Rare Disease Portfolio
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer.